|
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton's tyrosine kinase in Waldenstrom's macroglobulinemia
|
|
A new era for Waldenstrom macroglobulinemia: MYD88 L265P
|
|
MYD88 L265P in Waldenstrom's Macroglobulinemia, IgM Monoclonal Gammopathy, and other B-cell Lymphoproliferative Disorders using Conventional and Quantitative Allele-Specific PCR
|
|
Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration
|
|
Proceedings from the 7th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-7)
|
|
Proteasome inhibitors in Waldenström macroglobulinemia
|
|
Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
|
|
The Epidemiology of Herpes-Zoster in Patients with Newly Diagnosed Cancer
|
|
The genomic landscape of Waldenstrom's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like mutations, and small somatic deletions associated with B-cell lymphomagenesis.
|
|
Waldenstrom's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features
|
